SCHEMBL10074893

SCHEMBL10074893

COC(=O)c1ccc(O)c2nc3c(CN4CCCC4)c(O)c(-c4c(O)c(CN5CCCC5)c5nc6c(O)ccc(C(=O)OC)c6nc5c4O)c(O)c3nc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 7/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TSHR P16473 2/20 0.36
LMNA P02545 2/20 0.36
GAA P10253 2/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
CASP1 P29466 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
HTT P42858 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
MCL1 Q07820 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10075151 0.83 KDM4E (0.42) KDM4EMEN1KMT2ATSHRLMNA
SCHEMBL10075134 0.82 KDM4E (0.41) KDM4EALDH1A1MEN1KMT2ATSHR
SCHEMBL10074409 0.81 KDM4E (0.40) KDM4EMEN1KMT2ATSHRLMNA
SCHEMBL10075152 0.80 KDM4E (0.38) KDM4EMEN1KMT2ATSHRLMNA
SCHEMBL10075153 0.80 KDM4E (0.40) KDM4EALDH1A1MEN1KMT2ATSHR
SCHEMBL10075686 0.79 KDM4E (0.39) KDM4EALDH1A1MEN1KMT2ATSHR
SCHEMBL10075149 0.77 PTGER4 (0.38) KDM4EALDH1A1MEN1KMT2ATSHR
SCHEMBL10074598 0.76 HIF1A (0.44) KDM4EALDH1A1MEN1KMT2ATSHR
SCHEMBL10075558 0.75 MEN1 (0.39) KDM4EALDH1A1MEN1KMT2ATSHR
SCHEMBL3724952 0.75 KDM4E (0.57) KDM4EALDH1A1MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US claimed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US claimed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
WO-2012088438-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES MCL1, BCL3, BCL9 KDM4E 1427/4885ALDH1A1 2774/4885MEN1 521/4885
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES MCL1, BCL3, BCL2L1 KDM4E 709/4885ALDH1A1 1106/4885MEN1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.